Department of Radiation Oncology, London Regional Cancer Program, London Health Science Centre, University of Western Ontario, Ontario, Canada.
Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):696-700. doi: 10.1016/j.ijrobp.2011.01.010. Epub 2011 Mar 11.
To assess the impact of radiation management on male breast cancer (MBC) at London Regional Cancer Program (LRCP).
Men with a diagnosis of breast cancer referred to LRCP were reviewed. The seventh American Joint Committee on Cancer staging system was used. Patients treated with and without post-mastectomy radiation therapy (PMRT) were analyzed. Disease-free survival (DFS) was defined as time duration from diagnosis to first recurrence. Overall survival (OS) was defined as time duration from pathologic diagnosis to death or last follow-up with any death defined as an event. Survival estimates were obtained using Kaplan-Meier methodology.
From January 1977 to December 2006, 81 men had invasive ductal carcinoma. The median age was 65 (range, 35-87 years). There were 15 Stage I, 40 Stage II, 20 Stage III, and 6 Stage IV patients. Median follow-up time was 46 months (range, 1-225 months). Of the 75 patients treated with curative intent, 29 did not receive PMRT and 46 completed PMRT. Patients who received PMRT demonstrated no benefit in overall survival (p = 0.872) but significantly better local recurrence free survival (p < 0.001) compared with those who did not receive RT. There was trend toward improving locoregional recurrence with PMRT in patients with high-risk features (node-positive, advanced stage, and ≤ 2 mm or unknown surgical margin). The median, 5-year, and 10-year disease-free survival and overall survival for the 75 patients were 77.7 months, 66.3%, 32.7%, and 91.2 months, 73.9%, and 36.6%, respectively.
The experience at LRCP suggests that high-risk MBC patients should consider PMRT to improve their chance of local recurrence-free survival.
评估伦敦地区癌症项目（LRCP）中辐射管理对男性乳腺癌（MBC）的影响。
回顾了在 LRCP 就诊的男性乳腺癌患者。使用第七版美国癌症联合委员会分期系统。分析了接受和未接受乳房切除术放疗（PMRT）的患者。无病生存期（DFS）定义为从诊断到首次复发的时间间隔。总生存期（OS）定义为从病理诊断到死亡或最后一次随访的时间间隔，任何死亡均定义为事件。使用 Kaplan-Meier 方法获得生存估计。
从 1977 年 1 月至 2006 年 12 月，81 名男性患有浸润性导管癌。中位年龄为 65 岁（范围，35-87 岁）。15 例为 I 期，40 例为 II 期，20 例为 III 期，6 例为 IV 期。中位随访时间为 46 个月（范围，1-225 个月）。在 75 例接受根治性治疗的患者中，29 例未接受 PMRT，46 例完成 PMRT。接受 PMRT 的患者在总生存期方面没有获益（p = 0.872），但在局部无复发生存方面显著更好（p < 0.001）。在有高危特征（淋巴结阳性、晚期和/或手术切缘≤2 毫米或未知）的患者中，PMRT 具有改善局部区域复发的趋势。75 例患者的中位、5 年和 10 年无病生存率和总生存率分别为 77.7 个月、66.3%、32.7%和 91.2 个月、73.9%和 36.6%。
LRCP 的经验表明，高危 MBC 患者应考虑 PMRT，以提高其局部无复发生存率。
